Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tempest Therapeutics
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
Tempest Therapeutics to Present at H.C. Wainwright Conference
September 8, 2026
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
July 15, 2026
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
June 4, 2026
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
June 1, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 30, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 28, 2026
1
2
Next Page
→